Screen of FDA-approved drug library identifies maprotiline, an antibiofilm and antivirulence compound with QseC sensor-kinase dependent activity in Francisella novicida

Virulence

Volumn 6, Issue 5, 2015, Pages 487-503

  Dean, Scott N ^a,b   van Hoek, Monique L ^a,b  

^a National Center for Biodefense and Infectious Diseases   (United States)

^b GEORGE MASON UNIVERSITY   (United States)

Author keywords

Anti virulence; Biofilm; Chlorpromazine; FDA approved; Francisella; Galleria mellonella infection model; Maprotiline; Mouse model; QseC; Sensor histidine kinase; Toremifene; Two component system

Indexed keywords

CHLORPROMAZINE; MAPROTILINE; PROTEIN HISTIDINE KINASE; TOREMIFENE; VIRULENCE FACTOR; PROTEIN KINASE;

ANIMAL EXPERIMENT; ANTIBACTERIAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BIOFILM; CONTROLLED STUDY; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; FRANCISELLA NOVICIDA; IN VITRO STUDY; MOUSE; NONHUMAN; PATHOGENICITY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; ANIMAL; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; FEMALE; FRANCISELLA; GENE EXPRESSION REGULATION; GENETICS; GENOMIC ISLAND; GROWTH, DEVELOPMENT AND AGING; ISOLATION AND PURIFICATION; LARVA; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOTH; TULAREMIA; UNITED STATES; VIRULENCE;

ANIMALS; BIOFILMS; DISEASE MODELS, ANIMAL; FEMALE; FRANCISELLA; GENE EXPRESSION REGULATION, BACTERIAL; GENOMIC ISLANDS; HISTIDINE KINASE; LARVA; MAPROTILINE; MICE; MICROBIAL SENSITIVITY TESTS; MOTHS; PROTEIN KINASES; TULAREMIA; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VIRULENCE; VIRULENCE FACTORS;

EID: 84944452870     PISSN: 21505594     EISSN: 21505608     Source Type: Journal    
DOI: 10.1080/21505594.2015.1046029     Document Type: Article

References (58)

1. Johansen LM, Brannan JM, Delos SE, Sho'emaker CJ, Stossel A, Lear C, Hoffstrom BG, Dewald LE, Schornberg KL, Scully C, et al. FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci Transl Med 2013; 5:190ra79; PMID:23785035; http://dx.doi.org/10.1126/scitranslmed.3005471
2. Madrid PB, Chopra S, Manger ID, Gilfillan L, Keepers TR, Shurtleff AC, Green CE, Iyer LV, Dilks HH, Davey RA, et al. A systematic screen of FDA-approved drugs for inhibitors of biological threat agents. PLoS One 2013; 8:e60579; PMID:23577127; http://dx.doi. org/10.1371/journal.pone.0060579
3. Birdsell DN, Stewart T, Vogler AJ, Lawaczeck E, Diggs A, Sylvester TL, Buchhagen JL, Auerbach RK, Keim P, Wagner DM. Francisella tularensis subsp. novicida isolated from a human in Arizona. BMC Res Notes 2009; 2:223; PMID:19895698; http://dx.doi.org/ 10.1186/1756-0500-2-223
4. Hancock RE. Collateral damage. Nat Biotechnol 2014; 32:66-8; PMID:24406933; http://dx.doi.org/10.1038/ nbt.2779
5. Mackie RS, McKenney ES, van Hoek ML. Resistance of Francisella novicida to fosmidomycin associated with mutations in the glycerol-3-phosphate transporter. Front Microbiol 2012; 3:226; PMID:22905031; http://dx.doi.org/10.3389/ fmicb.2012.00226
6. Sutera V, Levert M, Burmeister WP, Schneider D, Maurin M. Evolution toward high-level fluoroquinolone resistance in Francisella species. J Antimicrob Chemother 2014; 69:101-10; PMID:23963236; http://dx. doi.org/10.1093/jac/dkt321
7. La Scola B, Elkarkouri K, Li W,Wahab T, Fournous G, Rolain JM, Biswas S, Drancourt M, Robert C, Audic S, et al. Rapid comparative genomic analysis for clinical microbiology: the Francisella tularensis paradigm. Genome Res 2008; 18:742-50; PMID:18407970; http:// dx.doi.org/10.1101/gr.071266.107
8. Gestin B, Valade E, Thibault F, Schneider D,MaurinM. Phenotypic and genetic characterization of macrolide resistance in Francisella tularensis subsp. holarctica biovar I. J Antimicrob Chemother 2010; 65:2359-67; PMID:20837574; http://dx.doi.org/10.1093/jac/dkq315
9. Maurin M. New anti-infective strategies for treatment of tularemia. Front Cell Infect Microbiol 2014; 4:115; PMID:25191647; http://dx.doi.org/10.3389/fcimb. 2014.00115
10. Rasko DA, Moreira CG, Li de R, Reading NC, Ritchie JM, Waldor MK, Williams N, Taussig R, Wei S, Roth M, et al. Targeting QseC signaling and virulence for antibiotic development. Science 2008; 321:1078-80; PMID:18719281; http://dx.doi.org/10.1126/science. 1160354
11. Curtis MM, Russell R, Moreira CG, Adebesin AM, Wang C, Williams NS, Taussig R, Stewart D, Zimmern P, Lu B, et al. QseC Inhibitors as an Antivirulence Approach for Gram-Negative Pathogens. mBio 2014; 5; PMID:25389178; http://dx.doi.org/10.1128/ mBio.02165-14
12. Rasko DA, Sperandio V. Anti-virulence strategies to combat bacteria-mediated disease. Nat Rev Drug Discov 2010; 9:117-28; PMID:20081869; http://dx.doi. org/10.1038/nrd3013
13. Verhoeven AB, Durham-Colleran MW, Pierson T, Boswell WT, Van Hoek ML. Francisella philomiragia biofilm formation and interaction with the aquatic protist Acanthamoeba castellanii. Biol Bull 2010; 219:178- 88; PMID:20972262
14. Bell BL, Mohapatra NP, Gunn JS. Regulation of virulence gene transcripts by the Francisella novicida orphan response regulator PmrA: role of phosphorylation and evidence of MglA/SspA interaction. Infect Immun 2010; 78:2189-98; PMID:20231408; http:// dx.doi.org/10.1128/IAI.00021-10
15. Durham-Colleran MW, Verhoeven AB, van Hoek ML. Francisella novicida forms in vitro biofilms mediated by an orphan response regulator. Microbial ecology 2010; 59:457-65; PMID:19763680; http://dx.doi.org/ 10.1007/s00248-009-9586-9
16. Sammons-Jackson WL, McClelland K, Manch-Citron JN, Metzger DW, Bakshi CS, Garcia E, Rasley A, Anderson BE. Generation and characterization of an attenuated mutant in a response regulator gene of Francisella tularensis live vaccine strain (LVS). DNA Cell Biol 2008; 27:387-403; PMID:18613792; http://dx. doi.org/10.1089/dna.2007.0687
17. Santic M, Molmeret M, Klose KE, Jones S, Kwaik YA. The Francisella tularensis pathogenicity island protein IglC and its regulator MglA are essential for modulating phagosome biogenesis and subsequent bacterial escape into the cytoplasm. Cellular microbiology 2005; 7:969-79; PMID:15953029; http://dx.doi.org/ 10.1111/j.1462-5822.2005.00526.x
18. Dai S, Mohapatra NP, Schlesinger LS, Gunn JS. Regulation of francisella tularensis virulence. Frontiers in microbiology 2010; 1:144; PMID:21687801
19. MohapatraNP, Soni S, Bell BL,Warren R, Ernst RK,Muszynski A, Carlson RW, Gunn JS. Identification of an orphan response regulator required for the virulence of Francisella spp. and transcription of pathogenicity island genes. Infect Immun 2007; 75:3305-14; PMID:17452468; http://dx.doi.org/10.1128/IAI.00351-07
20. Boguski MS, Mandl KD, Sukhatme VP. Drug discovery. Repurposing with a difference. Science 2009; 324:1394-5; PMID:19520944; http://dx.doi.org/ 10.1126/science.1169920
21. Sun R, Wang L. Inhibition of Mycoplasma pneumoniae growth by FDA-approved anticancer and antiviral nucleoside and nucleobase analogs. BMC Microbiol 2013; 13:184; PMID:23919755; http://dx.doi.org/ 10.1186/1471-2180-13-184
22. Bessoff K, Sateriale A, Lee KK, Huston CD. Drug repurposing screen reveals FDA-approved inhibitors of human HMG-CoA reductase and isoprenoid synthesis that block Cryptosporidium parvum growth. Antimicrob Agents Chemother 2013; 57:1804-14; PMID:23380723; http:// dx.doi.org/10.1128/AAC.02460-12
23. Amer LS, Bishop BM, van Hoek ML. Antimicrobial and antibiofilm activity of cathelicidins and short, synthetic peptides against Francisella. Biochem Biophys Res Commun 2010; 396:246-51; PMID:20399752; http://dx.doi.org/10.1016/j.bbrc.2010.04.073
24. Ahmad S, Hunter L, Qin A, Mann BJ, van Hoek ML. Azithromycin effectiveness against intracellular infections of Francisella. BMC microbiology 2010; 10:123; PMID:20416090; http://dx.doi.org/10.1186/1471- 2180-10-123
25. Han S, Bishop BM, vanHoekML. Antimicrobial activity of humanbeta-defensins andinduction by Francisella.Biochem BiophysRes Commun2008; 371:670-4; PMID:18452706; http://dx.doi.org/10.1016/j.bbrc.2008.04.092
26. McKenney ES, Sargent M, Khan H, Uh E, Jackson ER, San Jose G, Couch RD, Dowd CS, van Hoek ML. Lipophilic prodrugs of FR900098 are antimicrobial against Francisella novicida in vivo and in vitro and show GlpT independent efficacy. PLoS One 2012; 7: e38167; PMID:23077474; http://dx.doi.org/10.1371/ journal.pone.0038167
27. Ikaheimo I, Syrjala H, Karhukorpi J, Schildt R, Koskela M. In vitro antibiotic susceptibility of Francisella tularensis isolated from humans and animals. J Antimicrob Chemother 2000; 46:287-90; PMID:10933655; http://dx.doi.org/10.1093/jac/46.2.287
28. Sutera V, Caspar Y, Boisset S, Maurin M. A new dye uptake assay to test the activity of antibiotics against intracellular Francisella tularensis. Frontiers in cellular and infection microbiology 2014; 4:36; PMID:24672776; http://dx.doi.org/10.3389/fcimb.2014.00036
29. Wise R, Andrews JM, Thornber D. The in-vitro activity of cefdinir (FK482), a new oral cephalosporin. J Antimicrob Chemother 1991; 28:239-48; PMID:1778855; http://dx.doi.org/10.1093/jac/28.2.239
30. Tomaso H, Al Dahouk S, Hofer E, Splettstoesser WD, Treu TM, Dierich MP, Neubauer H. Antimicrobial susceptibilities of Austrian Francisella tularensis holarctica biovar II strains. Int J Antimicrob Agents 2005; 26:279-84; PMID:16143497; http://dx.doi.org/ 10.1016/j.ijantimicag.2005.07.003
31. Georgi E, Schacht E, Scholz HC, Splettstoesser WD. Standardized broth microdilution antimicrobial susceptibility testing of Francisella tularensis subsp. holarctica strains from Europe and rare Francisella species. J Antimicrob Chemother 2012; 67:2429-33; PMID:22763567; http://dx.doi.org/10.1093/jac/dks238
32. Cozzone AJ, Grangeasse C, Doublet P, Duclos B. Protein phosphorylation on tyrosine in bacteria. Arch Microbiol 2004; 181:171-81; PMID:14745484; http://dx.doi.org/10.1007/s00203-003-0640-6
33. Ilan O, Bloch Y, Frankel G, Ullrich H, Geider K, Rosenshine I. Protein tyrosine kinases in bacterial pathogens are associated with virulence and production of exopolysaccharide. Embo J 1999; 18:3241-8; PMID:10369665; http://dx.doi.org/10.1093/emboj/18.12.3241
34. Gerwig J, Kiley TB, Gunka K, Stanley-Wall N, Stulke J. The protein tyrosine kinases EpsB and PtkA differentially affect biofilm formation in Bacillus subtilis. Microbiology 2014; 160:682-91; PMID:24493247; http://dx.doi.org/10.1099/mic.0.074971-0
35. Yang H, Rudge DG, Koos JD, VaidialingamB, YangHJ, Pavletich NP. mTOR kinase structure, mechanism and regulation. Nature 2013; 497:217-23; PMID:23636326; http://dx.doi.org/10.1038/nature12122
36. Canova MJ, Molle V. Bacterial serine/threonine protein kinases in host-pathogen interactions. J Biol Chem 2014; 289:9473-9; PMID:24554701; http://dx.doi. org/10.1074/jbc.R113.529917
37. Lufkin EG, Sarkar S, Kulkarni PM, Ciaccia AV, Siddhanti S, Stock J, Plouffe L, Jr. Antiresorptive treatment of postmenopausal osteoporosis: review of randomized clinical studies and rationale for the Evista alendronate comparison (EVA) trial. Curr Med Res Opin 2004; 20:351-7; PMID:15025844; http://dx.doi. org/10.1185/030079904125003071
38. Howell A, Robertson JF, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, Vergote I, Erikstein B, Webster A, Morris C. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002; 20:3396-403; PMID:12177099; http://dx.doi.org/ 10.1200/JCO.2002.10.057
39. Huang E, Yousef AE. The lipopeptide antibiotic paenibacterin binds to the bacterial outer membrane and exerts bactericidal activity through cytoplasmic membrane damage. Appl Environ Microbiol 2014; 80:2700-4; PMID:24561581; http://dx.doi.org/ 10.1128/AEM.03775-13
40. Dean SN, Bishop BM, van Hoek ML. Susceptibility of Pseudomonas aeruginosa Biofilm to Alpha-Helical Peptides: D-enantiomer of LL-37. Frontiers in microbiology 2011; 2:128; PMID:21772832; http://dx.doi.org/ 10.3389/fmicb.2011.00128
41. Dean SN, Bishop BM, van Hoek ML. Natural and synthetic cathelicidin peptides with anti-microbial and anti-biofilm activity against Staphylococcus aureus. BMC microbiology 2011; 11:114; PMID:21605457; http://dx.doi.org/10.1186/1471-2180-11-114
42. Hurdle JG, O'Neill AJ, Chopra I, Lee RE. Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections. Nat Rev Microbiol 2011; 9:62-75; PMID:21164535; http://dx.doi. org/10.1038/nrmicro2474
43. Aperis G, Fuchs BB, Anderson CA, Warner JE, Calderwood SB,Mylonakis E. Galleriamellonella as amodel host to study infection by the Francisella tularensis live vaccine strain.Microbes Infect 2007; 9:729-34; PMID:17400503; http://dx.doi.org/10.1016/j.micinf.2007.02.016
44. Iljin K, Ketola K, Vainio P, Halonen P, Kohonen P, Fey V, Grafstrom RC, Perala M, Kallioniemi O. Highthroughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth. Clin Cancer Res 2009; 15:6070-8; PMID:19789329; http://dx.doi. org/10.1158/1078-0432.CCR-09-1035
45. Backman TW, Girke T. Cheminformatic analysis of high-throughput compound screens. Methods Mol Biol 2014; 1056:145-57; PMID:24306871; http://dx. doi.org/10.1007/978-1-62703-592-7_15
46. Lysko PG, Morse SA. Effects of steroid hormones on Neisseria gonorrhoeae. Antimicrobial agents and chemotherapy 1980; 18:281-8; PMID:6778380; http:// dx.doi.org/10.1128/AAC.18.2.281
47. Carlson JC, Gruber MY, Thompson JE. A study of the interaction between progesterone and membrane lipids. Endocrinology 1983; 113:190-4; PMID:6861696; http://dx.doi.org/10.1210/endo-113-1-190
48. Hosoda K, Shimomura H, Hayashi S, Yokota K, Hirai Y. Steroid hormones as bactericidal agents to Helicobacter pylori. FEMS Microbiol Lett 2011; 318:68-75; PMID:21306429; http://dx.doi.org/10.1111/j.1574- 6968.2011.02239.x
49. Stanley SA, Barczak AK, Silvis MR, Luo SS, Sogi K, Vokes M, Bray MA, Carpenter AE, Moore CB, Siddiqi N, et al. Identification of host-targeted small molecules that restrict intracellular Mycobacterium tuberculosis growth. PLoS Pathog 2014; 10:e1003946; PMID:24586159; http://dx. doi.org/10.1371/journal.ppat.1003946
50. Poon WW, Davis DE, Ha HT, Jonassen T, Rather PN, Clarke CF. Identification of Escherichia coli ubiB, a gene required for the first monooxygenase step in ubiquinone biosynthesis. J Bacteriol 2000; 182:5139-46; PMID:10960098; http://dx.doi.org/10.1128/ JB.182.18.5139-5146.2000
51. Baugh S, Ekanayaka AS, Piddock LJ, Webber MA. Loss of or inhibition of all multidrug resistance efflux pumps of Salmonella enterica serovar Typhimurium results in impaired ability to form a biofilm. J Antimicrob Chemother 2012; 67:2409-17; PMID:22733653; http:// dx.doi.org/10.1093/jac/dks228
52. Pierson T, Matrakas D, Taylor YU, Manyam G, Morozov VN, Zhou W, van Hoek ML. Proteomic characterization and functional analysis of outer membrane vesicles of Francisella novicida suggests possible role in virulence and use as a vaccine. J Proteome Res 2011; 10:954-67; PMID:21138299; http://dx.doi.org/ 10.1021/pr1009756
53. O'Toole GA. Microtiter dish biofilm formation assay. J Vis Exp 2011; PMID:21307833
54. Backman TW, Cao Y, Girke T. ChemMine tools: an online service for analyzing and clustering small molecules. Nucleic Acids Res 2011; 39:W486-91; PMID:21576229; http://dx.doi.org/10.1093/nar/ gkr320
55. Zhang H, Gao S, Lercher MJ, Hu S, Chen WH. Evol- View, an online tool for visualizing, annotating and managing phylogenetic trees. Nucleic Acids Res 2012; 40:W569-72; PMID:22695796; http://dx.doi.org/ 10.1093/nar/gks576
56. Pierson T, Matrakas D, Taylor YU, Manyam G, Morozov VN, Zhou W, van Hoek ML. Proteomic characterization and functional analysis of outer membrane vesicles of Francisella novicida suggests possible role in virulence and use as a vaccine. J Proteome Res 2011; 10:954-67; PMID:21138299; http://dx.doi.org/ 10.1021/pr1009756
57. Roy A, Kucukural A, Zhang Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nature protocols 2010; 5:725-38; PMID:20360767; http://dx.doi.org/10.1038/nprot.2010.5
58. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ. AutoDock4 and Auto- DockTools4: Automated docking with selective receptor flexibility. J Comput Chem 2009; 30:2785-91; PMID:19399780; http://dx.doi.org/10.1002/ jcc.21256